Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib vs imatinib in CP-CML patients with suboptimal early molecular response
CTR20132365Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, imatinib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Bristol Myers Squibb. Started Sep 2014; status: active.
02
Drugs
dasatinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on CTR20132365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132365.